Kilitch Drugs (India) Limited has announced changes to the timeline of its rights issue, affecting the credit and listing dates for the newly issued equity shares. The pharmaceutical company has rescheduled these key dates, pushing them back by one to two days.

Rights Issue Details

Kilitch Drugs is offering a rights issue of 13,98,463 equity shares with a face value of Rs. 10 each. The issue price is set at Rs. 357 per share, which includes a premium of Rs. 347. The total value of the rights issue amounts to Rs. 4,992.51 lakhs. Eligible shareholders can subscribe to the rights issue in the ratio of 2 rights equity shares for every 23 fully paid-up equity shares held as of the record date, which was July 15, 2025.

Revised Timeline

The company has made the following adjustments to the rights issue schedule:

• Credit of Rights Equity Shares: Rescheduled from August 25, 2025, to August 26, 2025
• Listing of Rights Equity Shares: Moved from August 26, 2025, to August 28, 2025

Allotment Process

According to the LODR (Listing Obligations and Disclosure Requirements) filing, the Board of Directors of Kilitch Drugs met on August 25, 2025, to finalize the basis of allotment and complete the allotment process. The allotment was made in accordance with the terms outlined in the Letter of Offer dated July 12, 2025, and in consultation with MUFG Intime India Private Limited, the Registrar to the Issue.

Impact on Share Capital

Following the rights issue allotment, Kilitch Drugs' paid-up equity share capital has been modified as follows:

The successful completion of this rights issue represents a significant step for Kilitch Drugs, potentially strengthening its financial position and providing capital for future growth initiatives. Investors and market participants will be closely watching the stock's performance when the newly issued shares are listed on August 28, 2025.

Shareholders and interested parties can find more information about the rights issue on the company's website at https://kilitch.com/investor-relations/ .

Kilitch Drugs (India) Limited, a pharmaceutical company, has announced a delay in the finalization of its Rights Issue allotment process. The company has pushed back the date for finalizing the basis of allotment and the allotment schedule from August 22, 2025, to August 25, 2025.

Rights Issue Details

The Rights Issue, which was initially approved by the company's Board of Directors on July 12, 2025, involves:

• Offering 13,98,463 equity shares
• Face value of Rs. 10.00 per share
• Issue price of Rs. 357.00 per share
• Total aggregation of Rs. 4,992.51 lakhs (approximately Rs. 49.93 crores)
• Rights ratio: 2 rights equity shares for every 23 fully paid-up equity shares held

Eligible shareholders, as determined on the record date of July 15, 2025, are entitled to participate in this Rights Issue.

Reason for Postponement

According to the company's official communication, the postponement decision was made in consultation with the National Stock Exchange of India Limited (NSE), which is the designated stock exchange for this issue, and the Registrar to the Issue. The company stated that the finalization and allotment process is currently underway and requires additional time.

Impact on Investors

This three-day delay may affect the timeline for investors expecting to receive their allotted shares. However, the company has not provided any information regarding changes to other key dates in the Rights Issue process.

Company Statement

Mukund Mehta, Managing Director of Kilitch Drugs (India) Limited, signed the official intimation to the stock exchanges regarding this postponement. The company has requested the stock exchanges to acknowledge and record this update.

Investors and market participants are advised to stay updated with any further announcements from the company regarding the Rights Issue process.

Note: This article is based on the latest available information as of August 22, 2025, and investors should consult official company communications for the most current updates.